Toggle Search
Toggle Menu

Michael Thomas

Director

Michael Thomas

Director

LinkedIn

Mike is a Director of Inova Personalized Health Accelerator. He is responsible for identifying and investing in all IPHA companies and expediting their achievement of value creating milestones.

As a healthcare technology CEO, Mike raised $125 million in capital and drove shareholder returns that ranged from 4x to 80x, including one IPO and one acquisition. Mike was most recently the founder and CEO of Appian Medical, a digital health firm that served the sleep apnea market. Previously, Mike was CEO of iSonea Ltd (ASX:ISN), a publicly traded global, mobile health app developer and medical device manufacturer in the respiratory disease market, where he increased the company’s market capitalization from $4MM to $250MM.

Earlier in his career, Mike was President and CEO of Sleep Solutions, a VC-­backed medical device manufacturer, EVP of Sales and Marketing for National Sleep Technologies (NST, acquired by GE Medical), and Vice President of Sales at Patient InfoSystems (NASDAQ: PATI). Mike began his career in sales and marketing at Merck and GlaxoWellcome.

He is currently a member of the Board of Directors for Circadiance LLC, a specialty CPAP mask manufacturer and is a former board member of AdvaMed, the global medical device association.

Mike graduated from Cornell University with a degree in Microbiology.

Return to Team Members

What's Happening

Jonathan Aberman: What do investors like about investing in D.C.? I asked them.

Nov 02, 2018

“We often talk about how important it is to attract more investors to our region, so I asked some... Read More

Why a DC Area Health System Is Training Tech Entrepreneurs – A Q&A with Rick Gordon of Inova

Oct 23, 2018

As published on the The Corporate Growth…Capital Style blog on October 22, 2018 by Ryan Schradin This Thursday (October 25, 2018), the... Read More

The Squeeze Continues…Early Stage Health Tech Deal Volume Falls to New Lows

Oct 15, 2018

by Michael Thomas Five consecutive quarters—and counting—of declining deal counts in pre-seed and seed-level investments for health technology startups... Read More